CHANGES IN HEMOSTASIS PARAMETERS DURING PREGNANCY COMPLICATED BY VARICOSE VEINS AND A DIFFERENTIAL APPROACH TO THEIR CORRECTION

Authors

  • Karimova Kamola Adhamjon kizi 2nd Department of Obstetrics and gynecology, 2nd year Master's student, Andijan State Medical Institute Author
  • Mukhitdinova Tokhtakhan Kadirovna Scientific supervisor, professor 2nd Department of Obstetrics and gynecology, Andijan State Medical Institute Author

Keywords:

Pregnancy complications, varicose veins, hemostasis, hypercoagulability, differential correction, D-dimer, low molecular weight heparin, venous thromboembolism, endothelial dysfunction.

Abstract

The physiological state of pregnancy naturally induces a profound hypercoagulable shift designed to minimize bleeding during parturition. However, when this natural adaptation is compounded by the presence of varicose veins of the lower extremities, the risk of developing life-threatening venous thromboembolism increases exponentially. This research investigates the specific alterations in hemostatic and rheological blood parameters among pregnant women suffering from varicose disease and evaluates the clinical efficacy of a differential, severity-based approach to pharmacological and mechanical correction. Through a comprehensive prospective clinical study involving serological analyses across different trimesters, researchers meticulously monitored markers such as fibrinogen, D-dimer, activated partial thromboplastin time, and soluble fibrin monomer complexes. The integrated literature review synthesizes current global perspectives on Virchow’s triad within the context of obstetric pathology, highlighting the detrimental synergy between venous stasis, endothelial dysfunction, and gestation-induced hypercoagulability. Empirical findings demonstrate that pregnant women with unmanaged varicose veins experience severe, pathological spikes in procoagulant markers during the third trimester, far exceeding normal physiological ranges. Conversely, the implementation of a targeted differential approach utilizing graduated compression therapy, phlebotonics, and low molecular weight heparins specifically tailored to the clinical and laboratory severity of the condition significantly stabilized the hemostatic profile. The discussion emphasizes the critical necessity of transitioning from a uniform prophylactic strategy to an individualized therapeutic paradigm. Ultimately, routine advanced hemostasis monitoring combined with differential correction is strongly advocated to mitigate thrombotic risks, thereby safeguarding both maternal and fetal well-being throughout the gestational period.

References

1.Brenner B. (2004). Haemostatic changes in pregnancy. Thrombosis Research, 114(5-6), 409-414.

2.Macklon N. S., Greer I. A., & Bowman A. W. (1997). An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. British Journal of Obstetrics and Gynaecology, 104(2), 191-197.

3.Nicolaides A. N., cardiovascular disease educational and research trust, European society of vascular surgery. (2000). Investigation of chronic venous insufficiency. Circulation, 102(20), E126-E163.

4.Bates S. M., Greer I. A., Middeldorp S., Veenstra D. L., Prabulos A. M., & Vandvik P. O. (2012). VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis. Chest, 141(2 Suppl), e691S-e736S.

5.Kline J. A., Williams G. W., & Hernandez-Nino J. (2005). D-dimer concentrations in normal pregnancy. New physiologic markers are needed. American Journal of Obstetrics and Gynecology, 193(1), 166-172.

6.Bergan J. J., Schmid-Schönbein G. W., Smith P. D., Nicolaides A. N., Boisseau M. R., & Eklof B. (2006). Chronic venous disease. The New England Journal of Medicine, 355(5), 488-498.

7.James A. H. (2009). Pregnancy-associated thrombosis. Hematology. American Society of Hematology. Education Program, 2009(1), 277-285.

8.Ercan S., Ozkan S., Yucel N., & Orcun A. (2015). Establishing reference intervals for D-dimer to normal pregnancy. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 187, 86-90.

9.Greer I. A., & Nelson-Piercy C. (2005). Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy. A systematic review of safety and efficacy. Blood, 106(2), 401-407.

10.Dargaud Y., & Négrier C. (2004). Heparin therapy during pregnancy. Its indications, benefits, and risks. Prescriber, 15(19), 23-30.

11.Kupferminc M. J., Eldor A., Steinman N., Many A., Bar-Am A., Jaffa A., Fait G., & Lessing J. B. (1999). Increased frequency of genetic thrombophilia in women with complications of pregnancy. The New England Journal of Medicine, 340(1), 9-13.

12.Pomp E. R., Lenselink A. M., Rosendaal F. R., & Doggen C. J. (2008). Pregnancy, the postpartum period and prothrombotic defects. Risk of venous thrombosis in the MEGA study. Journal of Thrombosis and Haemostasis, 6(4), 632-637.

Downloads

Published

2026-06-06